These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9633842)

  • 81. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
    Block MS; Charbonneau B; Vierkant RA; Fogarty Z; Bamlet WR; Pharoah PD; ; ; ; Rossing MA; Cramer D; Pearce CL; Schildkraut J; Menon U; Kjaer SK; Levine DA; Gronwald J; Culver HA; Whittemore AS; Karlan BY; Lambrechts D; Wentzensen N; Kupryjanczyk J; Chang-Claude J; Bandera EV; Hogdall E; Heitz F; Kaye SB; Fasching PA; Campbell I; Goodman MT; Pejovic T; Bean YT; Hays LE; Lurie G; Eccles D; Hein A; Beckmann MW; Ekici AB; Paul J; Brown R; Flanagan JM; Harter P; du Bois A; Schwaab I; Hogdall CK; Lundvall L; Olson SH; Orlow I; Paddock LE; Rudolph A; Eilber U; Dansonka-Mieszkowska A; Rzepecka IK; Ziolkowska-Seta I; Brinton LA; Yang H; Garcia-Closas M; Despierre E; Lambrechts S; Vergote I; Walsh CS; Lester J; Sieh W; McGuire V; Rothstein JH; Ziogas A; Lubiński J; Cybulski C; Menkiszak J; Jensen A; Gayther SA; Ramus SJ; Gentry-Maharaj A; Berchuck A; Wu AH; Pike MC; Van Den Berg D; Terry KL; Vitonis AF; Ramirez SM; Rider DN; Knutson KL; Sellers TA; Phelan CM; Doherty JA; Johnatty SE; deFazio A; Song H; Tyrer J; Kalli KR; Fridley BL; Cunningham JM; Goode EL
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1421-7. PubMed ID: 24740199
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma.
    Aune G; Stunes AK; Lian AM; Reseland JE; Tingulstad S; Torp SH; Syversen U
    Results Immunol; 2012; 2():190-5. PubMed ID: 24371583
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.
    Maine CJ; Aziz NH; Chatterjee J; Hayford C; Brewig N; Whilding L; George AJ; Ghaem-Maghami S
    Cancer Immunol Immunother; 2014 Mar; 63(3):215-24. PubMed ID: 24297569
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
    Staropoli N; Ciliberto D; Botta C; Fiorillo L; Gualtieri S; Salvino A; Tassone P; Tagliaferri P
    J Ovarian Res; 2013 Feb; 6(1):10. PubMed ID: 23388584
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer.
    Giri S; Karakoti A; Graham RP; Maguire JL; Reilly CM; Seal S; Rattan R; Shridhar V
    PLoS One; 2013; 8(1):e54578. PubMed ID: 23382918
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The detection, treatment, and biology of epithelial ovarian cancer.
    Gubbels JA; Claussen N; Kapur AK; Connor JP; Patankar MS
    J Ovarian Res; 2010 Mar; 3():8. PubMed ID: 20350313
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Mucins in ovarian cancer diagnosis and therapy.
    Chauhan SC; Kumar D; Jaggi M
    J Ovarian Res; 2009 Dec; 2():21. PubMed ID: 20034397
    [TBL] [Abstract][Full Text] [Related]  

  • 88. BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.
    Lee YK; Choi E; Kim MA; Park PG; Park NH; Lee H
    Br J Cancer; 2009 Aug; 101(3):504-10. PubMed ID: 19603021
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors.
    Liavaag AH; Dørum A; Fosså SD; Tropé C; Dahl AA
    BMC Cancer; 2009 Jan; 9():2. PubMed ID: 19121203
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.
    Mendiola M; Barriuso J; Redondo A; Mariño-Enríquez A; Madero R; Espinosa E; Vara JA; Sánchez-Navarro I; Hernández-Cortes G; Zamora P; Pérez-Fernández E; Miguel-Martín M; Suárez A; Palacios J; González-Barón M; Hardisson D
    PLoS One; 2008; 3(12):e4051. PubMed ID: 19112514
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.
    Singh AP; Senapati S; Ponnusamy MP; Jain M; Lele SM; Davis JS; Remmenga S; Batra SK
    Lancet Oncol; 2008 Nov; 9(11):1076-85. PubMed ID: 19012856
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.
    Ghadersohi A; Odunsi K; Zhang S; Azrak RG; Bundy BN; Manjili MH; Li F
    Int J Cancer; 2008 Sep; 123(6):1376-84. PubMed ID: 18567002
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Antigen-specific immunotherapy of cervical and ovarian cancer.
    Hung CF; Wu TC; Monie A; Roden R
    Immunol Rev; 2008 Apr; 222():43-69. PubMed ID: 18363994
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.
    Lassus H; Butzow R
    Br J Cancer; 2007 May; 96(10):1621-2; author reply 1623-4. PubMed ID: 17437016
    [No Abstract]   [Full Text] [Related]  

  • 95. Gene expression profiling of human ovarian tumours.
    Biade S; Marinucci M; Schick J; Roberts D; Workman G; Sage EH; O'Dwyer PJ; Livolsi VA; Johnson SW
    Br J Cancer; 2006 Oct; 95(8):1092-100. PubMed ID: 16969345
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.
    de Graeff P; Hall J; Crijns AP; de Bock GH; Paul J; Oien KA; ten Hoor KA; de Jong S; Hollema H; Bartlett JM; Brown R; van der Zee AG
    Br J Cancer; 2006 Sep; 95(5):627-33. PubMed ID: 16880779
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Prognostic factors in ovarian cancer.
    Friedlander ML
    Semin Oncol; 1998 Jun; 25(3):305-14. PubMed ID: 9633842
    [TBL] [Abstract][Full Text] [Related]  

  • 98. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
    Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
    Wu M; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
    [TBL] [Abstract][Full Text] [Related]  

  • 100. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.